Yıl: 2021 Cilt: 63 Sayı: 3 Sayfa Aralığı: 205 - 211 Metin Dili: İngilizce DOI: 10.4274/gulhane.galenos.2021.96268 İndeks Tarihi: 14-10-2021

Hematological indices in congenital male hypogonadism and the effects of testosterone replacement therapy: a retrospective study

Öz:
Aims: Mean platelet volume (MPV), platelet-to-lymphocyte ratio (PLR), and neutrophil-tolymphocyteratio (NLR) are surrogate markers of adverse cardiovascular (CV) outcomes. Theaim of this study was to investigate the platelet count, MPV level, PLR, NLR, and the effectof testosterone replacement therapy (TRT) on these parameters in patients with congenitalhypogonadotropic hypogonadism (CHH).Methods: Young male patients with CHH and healthy controls were recruited from theoutpatient setting. Blood pressures, height, weight, waist circumference (WC), and blood testsincluding triglyceride (TG) level, insulin, homeostatic model assessment-insulin resistance(HOMA-IR), PLR, and NLR were calculated between CHH patients and controls and followingTRT.Results: Sixty-six patients with CHH (mean age: 21.5±2.0 years) and 67 healthy controls(mean age: 21.9±1.3 years) were included in the study. CHH patients had higher plateletcount (262.9±50.7 vs 232.1±49.2, p=0.001), MPV level (8.63±0.87 vs 8.16±0.92, p=0.004), PLR(114.01±25.68 vs 100.59±25.49, p=0.003), WC (86.8±9.1 vs 83.7±7.9, p=0.04), TG (96.0 vs 80.0,p=0.02), insulin (9.41 vs 6.92, p<0.001), and HOMA-IR (1.95 vs 1.47, p<0.001) than healthycontrols. NLR was similar in both groups. After TRT, CHH patients showed significant elevationsin body mass index, WC, total testosterone, and HOMA-IR and reduction in high densitylipoprotein cholesterol level; however, platelet count, MPV, PLR, and NLR indices remainedunchanged. Total testosterone level was also correlated with platelet count, MPV, and PLR.Conclusions: This study showed higher platelet count and surrogate markers of CV risk such asMPV and PLR in patients with CHH. However, short time TRT did not show any effect on theseindices.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Traish AM, Saad F, Feeley RJ, Guay A. The dark side of testosterone deficiency: III. Cardiovascular disease. J Androl. 2009;30:477-494.
  • 2. Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab. 2006;91:843-850.
  • 3. Alkamel A, Shafiee A, Jalali A, Boroumand M, Nozari Y. The association between premature coronary artery disease and level of testosterone in young adult males. Arch Iran Med. 2014;17:545-550.
  • 4. Hu X, Rui L, Zhu T, et al. Low testosterone level in middleaged male patients with coronary artery disease. Eur J Intern Med. 2011;22:e133-136.
  • 5. Baetta R, Corsini A. Role of polymorphonuclear neutrophils in atherosclerosis: current state and future perspectives. Atherosclerosis. 2010;210:1-13.
  • 6. Elagizi A, Köhler TS, Lavie CJ. Testosterone and Cardiovascular Health. Mayo Clin Proc. 2018;93:83-100.
  • 7. Vizioli L, Muscari S, Muscari A. The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases. Int J Clin Pract. 2009;63:1509-1515.
  • 8. Kaya MG, Yarlioglues M, Gunebakmaz O, et al. Platelet activation and inflammatory response in patients with nondipper hypertension. Atherosclerosis. 2010;209:278-282.
  • 9. Hekimsoy Z, Payzin B, Ornek T, Kandoğan G. Mean platelet volume in Type 2 diabetic patients. J Diabetes Complications. 2004;18:173-176.
  • 10. Azab B, Shah N, Akerman M, McGinn JT Jr. Value of platelet/lymphocyte ratio as a predictor of all-cause mortality after non-ST-elevation myocardial infarction. J Thromb Thrombolysis. 2012;34:326-334.
  • 11. Ugur M, Gul M, Bozbay M, et al. The relationship between platelet to lymphocyte ratio and the clinical outcomes in ST elevation myocardial infarction underwent primary coronary intervention. Blood Coagul Fibrinolysis. 2014;25:806-811.
  • 12. Sunbul M, Gerin F, Durmus E, et al. Neutrophil to lymphocyte and platelet to lymphocyte ratio in patients with dipper versus non-dipper hypertension. Clin Exp Hypertens. 2014;36:217-221.
  • 13. Papa A, Emdin M, Passino C, Michelassi C, Battaglia D, Cocci F. Predictive value of elevated neutrophil-lymphocyte ratio on cardiac mortality in patients with stable coronary artery disease. Clin Chim Acta. 2008;395:27-31.
  • 14. Sonmez A, Haymana C, Aydogdu A, et al. Endothelial dysfunction, insulin resistance and inflammation in congenital hypogonadism, and the effect of testosterone replacement. Endocr J. 2015;62:605-613.
  • 15. Haymana C, Sonmez A, Aydogdu A, et al. Visceral adiposity index and triglyceride/high-density lipoprotein cholesterol ratio in hypogonadism. Arch Endocrinol Metab. 2017;61:282-287.
  • 16. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab. 2008;93:68-75.
  • 17. Khaw KT, Dowsett M, Folkerd E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation. 2007;116:2694- 2701.
  • 18. Dhindsa S, Miller MG, McWhirter CL, et al. Testosterone concentrations in diabetic and nondiabetic obese men. Diabetes Care. 2010;33:1186-1192.
  • 19. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR; Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86:724-731.
  • 20. Haffner SM. Sex hormones, obesity, fat distribution, type 2 diabetes and insulin resistance: epidemiological and clinical correlation. Int J Obes Relat Metab Disord. 2000;24 Suppl 2:S56-58.
  • 21. Stanworth RD, Kapoor D, Channer KS, Jones TH. Statin therapy is associated with lower total but not bioavailable or free testosterone in men with type 2 diabetes. Diabetes Care. 2009;32:541-546.
  • 22. Sonmez A, Haymana C, Bolu E, et al. Metabolic syndrome and the effect of testosterone treatment in young men with congenital hypogonadotropic hypogonadism. Eur J Endocrinol. 2011;164:759-764.
  • 23. Thaulow E, Erikssen J, Sandvik L, Stormorken H, Cohn PF. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation. 1991;84:613-617.
  • 24. Park Y, Schoene N, Harris W. Mean platelet volume as an indicator of platelet activation: methodological issues. Platelets. 2002;13:301-306.
  • 25. Chu SG, Becker RC, Berger PB, et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost. 2010;8:148-156.
  • 26. Shah B, Sha D, Xie D, Mohler ER, Berger JS. The relationship between diabetes, metabolic syndrome, and platelet activity as measured by mean platelet volume: the National Health And Nutrition Examination Survey, 1999- 2004. Diabetes Care. 2012;35:1074-1078.
  • 27. Carlioglu A, Durmaz SA, Kibar YI, Ozturk Y, Tay A. Mean platelet volume in a patient with male hypogonadotropic hypogonadism: the relationship between low testosterone, metabolic syndrome, impaired fasting glucose and cardiovascular risk. Blood Coagul Fibrinolysis. 2015;26:811- 815.
  • 28. Horne BD, Anderson JL, John JM, et al. Which white blood cell subtypes predict increased cardiovascular risk? J Am Coll Cardiol. 2005;45:1638-1643.
  • 29. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154:899-906.
  • 30. Li JY, Zhu JC, Dou JT, et al. Effects of androgen supplementation therapy on partial androgen deficiency in the aging male: a preliminary study. Aging Male. 2002;5:47- 51.
  • 31. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363:109-122.
  • 32. Vigen R, O’Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310:1829-1836.
APA Demirci I, haymana c, DEMİR O, akın o, Meric C, Aydogdu A, Sonmez A (2021). Hematological indices in congenital male hypogonadism and the effects of testosterone replacement therapy: a retrospective study. , 205 - 211. 10.4274/gulhane.galenos.2021.96268
Chicago Demirci Ibrahim,haymana cem,DEMİR ORHAN,akın onur,Meric Coskun,Aydogdu Aydogan,Sonmez Alper Hematological indices in congenital male hypogonadism and the effects of testosterone replacement therapy: a retrospective study. (2021): 205 - 211. 10.4274/gulhane.galenos.2021.96268
MLA Demirci Ibrahim,haymana cem,DEMİR ORHAN,akın onur,Meric Coskun,Aydogdu Aydogan,Sonmez Alper Hematological indices in congenital male hypogonadism and the effects of testosterone replacement therapy: a retrospective study. , 2021, ss.205 - 211. 10.4274/gulhane.galenos.2021.96268
AMA Demirci I,haymana c,DEMİR O,akın o,Meric C,Aydogdu A,Sonmez A Hematological indices in congenital male hypogonadism and the effects of testosterone replacement therapy: a retrospective study. . 2021; 205 - 211. 10.4274/gulhane.galenos.2021.96268
Vancouver Demirci I,haymana c,DEMİR O,akın o,Meric C,Aydogdu A,Sonmez A Hematological indices in congenital male hypogonadism and the effects of testosterone replacement therapy: a retrospective study. . 2021; 205 - 211. 10.4274/gulhane.galenos.2021.96268
IEEE Demirci I,haymana c,DEMİR O,akın o,Meric C,Aydogdu A,Sonmez A "Hematological indices in congenital male hypogonadism and the effects of testosterone replacement therapy: a retrospective study." , ss.205 - 211, 2021. 10.4274/gulhane.galenos.2021.96268
ISNAD Demirci, Ibrahim vd. "Hematological indices in congenital male hypogonadism and the effects of testosterone replacement therapy: a retrospective study". (2021), 205-211. https://doi.org/10.4274/gulhane.galenos.2021.96268
APA Demirci I, haymana c, DEMİR O, akın o, Meric C, Aydogdu A, Sonmez A (2021). Hematological indices in congenital male hypogonadism and the effects of testosterone replacement therapy: a retrospective study. Gülhane Tıp Dergisi, 63(3), 205 - 211. 10.4274/gulhane.galenos.2021.96268
Chicago Demirci Ibrahim,haymana cem,DEMİR ORHAN,akın onur,Meric Coskun,Aydogdu Aydogan,Sonmez Alper Hematological indices in congenital male hypogonadism and the effects of testosterone replacement therapy: a retrospective study. Gülhane Tıp Dergisi 63, no.3 (2021): 205 - 211. 10.4274/gulhane.galenos.2021.96268
MLA Demirci Ibrahim,haymana cem,DEMİR ORHAN,akın onur,Meric Coskun,Aydogdu Aydogan,Sonmez Alper Hematological indices in congenital male hypogonadism and the effects of testosterone replacement therapy: a retrospective study. Gülhane Tıp Dergisi, vol.63, no.3, 2021, ss.205 - 211. 10.4274/gulhane.galenos.2021.96268
AMA Demirci I,haymana c,DEMİR O,akın o,Meric C,Aydogdu A,Sonmez A Hematological indices in congenital male hypogonadism and the effects of testosterone replacement therapy: a retrospective study. Gülhane Tıp Dergisi. 2021; 63(3): 205 - 211. 10.4274/gulhane.galenos.2021.96268
Vancouver Demirci I,haymana c,DEMİR O,akın o,Meric C,Aydogdu A,Sonmez A Hematological indices in congenital male hypogonadism and the effects of testosterone replacement therapy: a retrospective study. Gülhane Tıp Dergisi. 2021; 63(3): 205 - 211. 10.4274/gulhane.galenos.2021.96268
IEEE Demirci I,haymana c,DEMİR O,akın o,Meric C,Aydogdu A,Sonmez A "Hematological indices in congenital male hypogonadism and the effects of testosterone replacement therapy: a retrospective study." Gülhane Tıp Dergisi, 63, ss.205 - 211, 2021. 10.4274/gulhane.galenos.2021.96268
ISNAD Demirci, Ibrahim vd. "Hematological indices in congenital male hypogonadism and the effects of testosterone replacement therapy: a retrospective study". Gülhane Tıp Dergisi 63/3 (2021), 205-211. https://doi.org/10.4274/gulhane.galenos.2021.96268